HopeStage
Back to all studies
UnknownNCT06358014

Assessment of the Improvement in Cognitive Levels of Postmenopausal Depression Patients by Estrogen

Medication studyUp to age 70China
The study in practice

Understand this study

Who could participate?

Listed age limits: up to 70 years.

Listed locations
BeijingSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: May 12, 2023
Recruitment status
Unknown
Enrollment listed in the registry
40
Sponsor
Xiao Wang
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Locations
China
Age range
Up to 70 Years
Official registry ID
NCT06358014
Official title
Show the full official title

Beijing Anding Hospital Affiliated to Capital Medical University

Recruitment & locations

Status unknown

Beijing

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Xiao Wang.

Does this study involve medication?

Yes. The study involves medication, including Fematon (estradiol/estradiol-norethindrone acetate combination tablet package)+SSRIs and SSRIs.

Who can participate?

Listed age limits: up to 70 years.

Want to explore more studies?

Explore studies